SCHEMBL1574832

SCHEMBL1574832

CC(C)(C)OC(=O)N1CCN(C2CN(C(=O)Nc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.58
STS P08842 1/20 0.49
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
S1PR2 O95136 1/20 0.45
NAMPT P43490 2/20 0.44
TACR1 P25103 3/20 0.43
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41
GRIN2B Q13224 1/20 0.41
SHMT2 P34897 1/20 0.40
PAK1 Q13153 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575229 0.84 GRIN2B (0.45) MAPTS1PR2GRIN2BPAK1
SCHEMBL1574810 0.82 CCR2 (0.47) MAPTS1PR2GRIN2BSHMT2PAK1
SCHEMBL1576237 0.81 GAA (0.47) S1PR2GRIN2BSHMT2PAK1
SCHEMBL1575624 0.81 GAA (0.47) S1PR2GRIN2BSHMT2PAK1
SCHEMBL1575401 0.79 GRIN2B (0.45) MAPTS1PR2GRIN2BPAK1
SCHEMBL1575699 0.79 GRIN2B (0.45) MAPTS1PR2GRIN2BPAK1
SCHEMBL1575049 0.79 DCUN1D1 (0.46) S1PR2GRIN2BPAK1
SCHEMBL1575349 0.78 CYP2C9 (0.47) MEN1KMT2AS1PR2NAMPTGRIN2B
SCHEMBL1575524 0.78 CCR2 (0.45) MAPTS1PR2TACR1GRIN2BPAK1
SCHEMBL1574330 0.78 MAPT (0.53) MAPTNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-B1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO (JP) 2015-02-25 EP disclosed
EP-2308562-B1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO (JP) 2015-02-25 EP disclosed
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB MAPT 3908/4885STS 1120/4885MEN1 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.